000127997 001__ 127997
000127997 005__ 20240228145528.0
000127997 0247_ $$2doi$$a10.1093/neuonc/now290
000127997 0247_ $$2pmid$$apmid:28096493
000127997 0247_ $$2pmc$$apmc:PMC5570252
000127997 0247_ $$2ISSN$$a1522-8517
000127997 0247_ $$2ISSN$$a1523-5866
000127997 037__ $$aDKFZ-2017-04019
000127997 041__ $$aeng
000127997 082__ $$a610
000127997 1001_ $$aBerghoff, Anna S$$b0
000127997 245__ $$aCombining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.
000127997 260__ $$aOxford$$bOxford Univ. Press$$c2017
000127997 3367_ $$2DRIVER$$aarticle
000127997 3367_ $$2DataCite$$aOutput Types/Journal article
000127997 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1509716330_12187
000127997 3367_ $$2BibTeX$$aARTICLE
000127997 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127997 3367_ $$00$$2EndNote$$aJournal Article
000127997 520__ $$aWe aimed to investigate the potential of standard hematologic and serum biochemical parameters to provide an independent and substantial contribution to the prediction of survival in patients with newly diagnosed brain metastases (BM).Hemoglobin, white blood cell count, platelet count, serum albumin, creatinine, lactate dehydrogenase (LDH), and C-reactive protein (CRP) were assessed at diagnosis of BM in a discovery cohort of 1200 cancer patients. A multivariable Cox regression model was used to derive the LabBM score. The LabBM score was externally validated in an independent cohort consisting of 366 patients.Hemoglobin below lower limit of normal (<LLN; hazard ratio [HR] 1.28; P = .001), platelet count <LLN (HR: 1.36; P = .013), albumin <LLN (HR: 1.19; P = .038), LDH above upper limit of normal (>ULN; HR: 1.51; P < .001), and CRP >ULN (HR: 1.52; P < .001) were associated with survival in a multivariable Cox regression model and were included in the calculation of the LabBM score. Multivariable analysis including the LabBM score and graded prognostic assessment class revealed an independent and significant association of the LabBM score with overall survival (OS) (HR: 1.42; 95% CI: 1.29-1.57; P < .001). The strong and independent association of LabBM score (HR: 1.93; 95% CI: 1.54-2.42) with OS prognosis was confirmed in the validation cohort.Standard clinical blood parameters, combined in the easy-to-calculate LabBM score, provide strong and independent prognostic information in patients with BM. The LabBM score is an objective, inexpensive, and reproducible tool to plan clinical management strategies in BM patients and to improve patient selection and stratification for clinical trials.
000127997 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000127997 588__ $$aDataset connected to CrossRef, PubMed,
000127997 7001_ $$aWolpert, Fabian$$b1
000127997 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b2$$udkfz
000127997 7001_ $$aKoller, Romina$$b3
000127997 7001_ $$aWidhalm, Georg$$b4
000127997 7001_ $$aGatterbauer, Brigitte$$b5
000127997 7001_ $$aDieckmann, Karin$$b6
000127997 7001_ $$aBirner, Peter$$b7
000127997 7001_ $$aBartsch, Rupert$$b8
000127997 7001_ $$aZielinski, Christoph C$$b9
000127997 7001_ $$aWeller, Michael$$b10
000127997 7001_ $$aPreusser, Matthias$$b11
000127997 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/now290$$gVol. 19, no. 9, p. now290 -$$n9$$p1255-1262$$tNeuro-Oncology$$v19$$x1523-5866$$y2017
000127997 909CO $$ooai:inrepo02.dkfz.de:127997$$pVDB
000127997 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000127997 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000127997 9141_ $$y2017
000127997 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000127997 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000127997 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2015
000127997 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127997 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127997 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127997 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127997 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127997 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127997 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000127997 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2015
000127997 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000127997 980__ $$ajournal
000127997 980__ $$aVDB
000127997 980__ $$aI:(DE-He78)C060-20160331
000127997 980__ $$aUNRESTRICTED